A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.

Preclinical studies of overlapping 15mer peptides, spanning SIV, SHIV or HIV, pulsed on autologous PBMC ex vivo have demonstrated high level, virus-specific T cell responses and viral suppression in non-human primates (NHP). Opal-HIV-Gag(c) consists of 120 synthetic 15mer peptides spanning Clade C,...

Celý popis

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Akil Jackson, Henrik N Kløverpris, Marta Boffito, Amanda Handley, Mark Atkins, Peter Hayes, Jill Gilmour, Lynn Riddel, Fabian Chen, Melanie Bailey-Tippets, Bruce Walker, Jim Ackland, Mark Sullivan, Philip Goulder
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2013-01-01
Edice:	PLoS ONE
On-line přístup:	http://europepmc.org/articles/PMC3775760?pdf=render
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

A randomised, placebo-controlled, first-in-human study of a novel clade C therapeutic peptide vaccine administered ex vivo to autologous white blood cells in HIV infected individuals.

Podobné jednotky